Syzent’s business philosophy is based on three principles:
- Commitment to partner goals
Syzent’s work is characterized by clear strategic thinking, evidence-based conclusions and forward movement. Syzent acts as a catalyst to generate reactions among the management team, potential investors and partners. Syzent partners with clients to implement initiatives.
Syzent always discloses potential conflicts of interest, and to prevent them, will only take on one client per therapeutic area or type of medical device.
Michael Atkin is the founder and CEO of Syzent Partners Ltd. He has many years of experience advancing early stage life sciences products and technologies towards commercialization. He has successfully obtained investment funding for spin-out companies, advanced therapeutics into clinical trials, merged biotechnology companies and licensed technologies from and to biotech. and pharma companies. He has a track record of success in executing business development strategies.
When additional skills are required to serve client needs, Syzent will strengthen the team with experienced professionals, who will be fully briefed on client needs and project background.
Website Design by MMICnet
The Syzent logo includes a 2006 solar eclipse photograph from NASA. The original image may be found here.
Lab photos by Michael Atkin; photograph of Michael Atkin by Tobias Atkin. All photographs shot on Hasselblad 500 C/M using Carl Zeiss lens and Ilford film. Photographs may be reproduced for non-commercial purposes with attribution to Syzent.com website. We thank Professor Gabriella Gobbi, MD, PhD and Professor Sylvain Martel, PhD for providing permission to take photographs in their laboratories.
Website text and photographs copyright © 2012 to 2018, Syzent Partners Ltd.